La chaîne d'options affiche les données clés des options sur actions de UCB à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour UCB..

UCB (OTC:UCBJF) Stock, Chaîne d'Options

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB SA

Biotech

Large Cap

News

Health Care

Legal

General

RFK Jr. poursuivi par Eli Lilly et Amgen pour le programme de réduction des médicaments

قامت إيلي ليلي وأمجين بمقاضاة آر إف كيه جونيور بسبب برنامج خصم الأدوية

RFK Jr.がEli Lilly、Amgenによって薬割引プログラムについて訴えられる

RFK Jr.가 Eli Lilly와 Amgen에 의해 약물 할인 프로그램으로 소송을 당했다

Barclays Remains a Buy on UCB SA (0NZT)

Barclays Sticks to Their Buy Rating for UCB SA (0NZT)

Macquarie Healthcare Fund Q2 2025 Commentary

Small Cap

Press Releases

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Comments

UCB

UCB (UCBJF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL